Compare UIS & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UIS | ARCT |
|---|---|---|
| Founded | 1942 | 2013 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 192.6M |
| IPO Year | 1994 | 2019 |
| Metric | UIS | ARCT |
|---|---|---|
| Price | $2.18 | $7.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $5.88 | ★ $38.44 |
| AVG Volume (30 Days) | ★ 796.5K | 389.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,008,400,000.00 | $152,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.11 | $5.85 |
| 52 Week High | $5.33 | $24.14 |
| Indicator | UIS | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 29.10 | 54.35 |
| Support Level | $2.16 | $7.05 |
| Resistance Level | $2.39 | $7.68 |
| Average True Range (ATR) | 0.13 | 0.45 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 9.34 | 54.74 |
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.